Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUniversity of Alberta
About this trial
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.
This study involves (3) in-person study visits. At each visit, participants will be asked to:
* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.
Eligibility criteria
Qualifiers
Adults 18-80 years of age
Starting semaglutide for type 2 diabetes or weight loss
Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Disqualifiers
Current use of semaglutide for more than 2 weeks
Major recent heart issues or other severe health conditions
Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
Dependence on a mobility aid (unable to participate in exercise MRI)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov